Zylox-Tonbridge Medical Technology Co (HKSE:02190) Moat Score: 0/10 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02190 Zylox-Tonbridge Medical Technology Co Ltd HKSE:02190
82 GF Score
Price HK$19.95
GF Value HK$35.80
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zylox-Tonbridge Medical Technology Co Moat Score?

Zylox-Tonbridge Medical Technology Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Zylox-Tonbridge Medical Technology Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zylox-Tonbridge Medical Technology Co might have No Moat - No discernible moat.

Zylox-Tonbridge Medical Technology Co  (HKSE:02190) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zylox-Tonbridge Medical Technology Co Moat Score Related Terms

HKSE:02190
82GF Score
Zylox-Tonbridge Medical Technology Co Ltd HKSE:02190
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zylox-Tonbridge Medical Technology Co (HKSE:02190) Overvalued in 2026?

Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued. The current stock price of HK$19.95 is trading 44.3% below its estimated GF Value™ of HK$35.80. GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.

Key valuation signals for HKSE:02190:

  • Moat Score: 0
  • GF Value™: HK$35.80 vs. price of HK$19.95 (44.3% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKSE:02190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zylox-Tonbridge Medical Technology Co Business Description

Other Exchanges 818:Germany
Address 270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
82GF Score

Get the complete analysis for HKSE:02190

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$19.95
Price
HK$35.80
GF Value